Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDVYNE Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.29 | -$0.29 | -$0.29 |
| Q2 2025 | 1 | -$0.29 | -$0.29 | -$0.29 |
| Q3 2025 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q4 2025 | 1 | -$0.31 | -$0.31 | -$0.31 |
VYNE Therapeutics Inc. Earnings Date And Information
VYNE Therapeutics Inc. last posted its earnings results on Thursday, March 6th, 2025. The company reported $-0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.31 by $0.03. The company had revenue of 84,000 for the quarter and had revenue of 501,000 for the year. VYNE Therapeutics Inc. has generated $-1 earnings per share over the last year ($-0.94 diluted earnings per share) and currently has a price-to-earnings ratio of -2.03. VYNE Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
VYNE Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/06/2025 | Q4 2024 | -$0.31 | -$0.28 | 0.03 | $150,000 | $84,000 |
| 11/07/2024 | Q3 2024 | -$0.24 | -$0.29 | -0.05 | $110,000 | $121,000 |
| 08/14/2024 | Q2 2024 | -$0.19 | -$0.22 | -0.03 | $110,000 | $198,000 |
| 05/09/2024 | Q1 2024 | -$0.24 | -$0.15 | 0.09 | N/A | $98,000 |
| 03/01/2024 | Q4 2023 | N/A | -$0.20 | N/A | $150,000 | $76,000 |
| 11/13/2023 | Q3 2023 | -$0.76 | -$2.01 | -1.25 | $150,000 | $114,000 |
| 08/14/2023 | Q2 2023 | -$1.99 | -$3.08 | -1.09 | $50,000 | $135,000 |
| 05/11/2023 | Q1 2023 | -$2.50 | -$1.72 | 0.78 | N/A | $99,000 |
| 03/14/2023 | Q4 2022 | N/A | -$2.60 | N/A | N/A | $6,000 |
| 11/14/2022 | Q3 2022 | N/A | -$2.94 | N/A | $50,000 | $167,000 |
| 08/12/2022 | Q2 2022 | -$2.70 | -$2.63 | 0.07 | $100,000 | $126,000 |
| 05/12/2022 | Q1 2022 | -$2.70 | $1.52 | 4.22 | N/A | $178,000 |
| 03/17/2022 | Q4 2021 | -$4.68 | -$3.89 | 0.79 | N/A | $2.29 M |
| 11/10/2021 | Q3 2021 | -$6.12 | -$7.36 | -1.24 | $4.76 M | $4.09 M |
| 08/12/2021 | Q2 2021 | -$6.29 | -$6.98 | -0.69 | $6.35 M | $4.26 M |
| 05/06/2021 | Q1 2021 | -$7.19 | -$7.57 | -0.38 | N/A | $4.12 M |
| 03/04/2021 | Q4 2020 | -$8.99 | -$8.54 | 0.45 | N/A | $4.29 M |
| 11/05/2020 | Q3 2020 | -$12.23 | -$10.61 | 1.62 | $3.31 M | $3.27 M |
| 08/06/2020 | Q2 2020 | -$17.88 | -$86.95 | -69.07 | $1.59 M | $11.69 M |
| 05/11/2020 | Q1 2020 | -$38.88 | -$68.15 | -29.27 | N/A | $1.75 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
VYNE Therapeutics Inc. Earnings: FAQ's
VYNE Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based offlast year's report dates.
In the previous quarter, VYNE Therapeutics Inc. (:VYNE) reported $-0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.31 by $0.03.
The conference call for VYNE Therapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for VYNE Therapeutics Inc.'s latest earnings report can be read online.
VYNE Therapeutics Inc. (:VYNE) has a recorded annual revenue of $501,000.
VYNE Therapeutics Inc. (:VYNE) has a recorded net income of $-39,834,000.VYNE Therapeutics Inc. has generated $-0.94 earnings per share over the last four quarters.
VYNE Therapeutics Inc. (:VYNE) has a price-to-earnings ratio of -2.03 and price/earnings-to-growth ratio is 0.22.